← Eichor
Study identifier: NCT06993571 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor

Condition: Parkinson's Disease (PD) · Tremor  ·  Sponsor: Universitätsklinikum Hamburg-Eppendorf

PhaseNA
Planned participants10
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by different motor symptoms, including tremor, which is particularly difficult to manage. Common treatments, such as dopaminergic therapy, can have limitations in efficacy. Recent advancements in non-invasive brain stimulation, specifically phase-adaptive transcranial alternating current stimulation (tACS), offer a promising approach to reduce PD tremor. In the current project, a newly developed closed-loop system delivers precisely synchronized cerebellar tACS by aligning stimulation with the intrinsic hand tremor signal. The study will assess the efficacy of this novel approach to reduce hand tremor in PD patients.

This description comes directly from the study's public registry record.

Talk to the study team

Simone Zittel, Dr. med.  ·  +49 40 7410 53770  ·  s.zittel-dirks@uke.de

Always discuss trial participation with your own doctor first.

Locations (1)

Universitätsklinikum Hamburg-EppendorfHamburg, Free and Hanseatic City of Hamburg, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06993571